QUEST DIAGNOSTICS INC
DGXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for DGX. That does not mean none is planned.
Get an email about DGX's next catalysts
Track QUEST DIAGNOSTICS (DGX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Website| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
oregovomab | Phase 2 | Ovarian Neoplasms | - | - |
Melatonin | Phase 2 | Pain, Postoperative | - | - |
Frequently asked questions
What is in QUEST DIAGNOSTICS INC's drug pipeline?→
CatalystAlert tracks 2 drug candidates in QUEST DIAGNOSTICS INC's (DGX) pipeline across Phase 2. Its lead program is Melatonin (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is QUEST DIAGNOSTICS INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for QUEST DIAGNOSTICS INC (DGX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DGX biotech catalysts?→
Add DGX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow QUEST DIAGNOSTICS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.